Your browser doesn't support javascript.
loading
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis.
Hamzavi, Seyedeh Sadigheh; Bahrololoom, Rosemina; Saeb, Sepideh; Marandi, Nahid Heydari; Hosseini, Marzieh; Hesam Abadi, Alimohammad Keshtvarz; Jamalidoust, Marzieh.
Afiliación
  • Hamzavi SS; Department of Pediatrics, Namazi Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Bahrololoom R; Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, 71936-13311, Iran.
  • Saeb S; Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, 71936-13311, Iran. bahrololoom.rm@gmail.com.
  • Marandi NH; Department of Virology, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Hosseini M; Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, 71936-13311, Iran.
  • Hesam Abadi AK; Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, 71936-13311, Iran.
  • Jamalidoust M; Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran.
BMC Immunol ; 25(1): 35, 2024 Jun 19.
Article en En | MEDLINE | ID: mdl-38898409
ABSTRACT

BACKGROUND:

For the past three years, the pandemic has had a major effect on global public health, mainly on those with underlying medical conditions, such as people living with Multiple Sclerosis. Vaccination among this group is of great importance, and the long-term impacts of vaccination and its safety on the health of these patients will continue to be revealed. Therefore, risks related to vaccination and immune response need to be assessed. The objective here was to characterize the immune response, short-term safety, and the effects of multiple variables on these factors after COVID-19 vaccination (mainly Sinopharm) among people with Multiple Sclerosis. We assessed the short-term safety and humoral SARS-COV-2 anti-RBD IgG response using a data collection form and Immunoassay, respectively.

RESULTS:

No severe adverse events or MS relapse was observed. Myalgia/body pain (26.7%), low-grade fever (22.2%), and mild headache (15.6%) were the most common adverse events. The use and type of vaccine influenced the frequency of side effects with a p-value < 0.0001. Regarding immune response, patients on rituximab and fingolimod had a lower antibody titer compared to other medications. With a significant difference, hybrid immunity (p-value 0.047) and type of DMTs (p-value 0.017) affected the humoral response.

CONCLUSION:

There is a low incidence of serious adverse effects, MS worsening or relapse after COVID-19 vaccination, and mainly, side effects are similar to that of the general population. It appears that treatment with various disease-modifying therapies does not induce or worsen the post-vaccination side effects, although some, including Rituximab and fingolimod, may affect the immunity induced after vaccination.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunidad Humoral / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales / Esclerosis Múltiple Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunidad Humoral / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales / Esclerosis Múltiple Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido